The potential roles of JAK/STAT signaling in the progression of osteoarthritis

Osteoarthritis (OA) is an age-related chronic progressive degenerative disease that induces persistent pain and disabilities. The development of OA is a complex process, and the risk factors are various, including aging, genetics, trauma and altered biomechanics. Inflammation and immunity play an im...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 13; p. 1069057
Main Authors Zhou, Qingluo, Ren, Qun, Jiao, Linhui, Huang, Jishang, Yi, Jun, Chen, Jincai, Lai, Jinliang, Ji, Guanglin, Zheng, Tiansheng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.11.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Osteoarthritis (OA) is an age-related chronic progressive degenerative disease that induces persistent pain and disabilities. The development of OA is a complex process, and the risk factors are various, including aging, genetics, trauma and altered biomechanics. Inflammation and immunity play an important role in the pathogenesis of OA. JAK/STAT pathway is one of the most prominent intracellular signaling pathways, regulating cell proliferation, differentiation, and apoptosis. Inflammatory factors can act as the initiators of JAK/STAT pathway, which is implicated in the pathophysiological activity of chondrocyte. In this article, we provide a review on the importance of JAK/STAT pathway in the pathological development of OA. Potentially, JAK/STAT pathway becomes a therapeutic target for managing OA.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: An Qin, Shanghai Jiao Tong University, China
Reviewed by: Wataru Ariyoshi, Kyushu Dental University, Japan; Farhath Sultana, Icahn School of Medicine at Mount Sinai, United States
This article was submitted to Bone Research, a section of the journal Frontiers in Endocrinology
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2022.1069057